Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection

NCT ID: NCT05594550

Last Updated: 2022-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcopenia is a risk factor for adverse outcome in critically ill patients. Sarcopenia might be estimated from muscle surface measure on tomodensitometry.

The purpose of the study is to identify if muscle surfaces measured on thoracic tomodensitometry are associated with mortality in patients with acute respiratory distress syndrome due to SARS-Cov-2.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Distress Syndrom (SARS-Cov 2)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

28-day survival

Alive 28 days after intensive care admission

Data collection

Intervention Type OTHER

Demographic data:

Age, Sex, weight, height, main history and treatments.

\- Biological data: CRP, PCT, albumin, pre-albumin

analysis of thoracic scans

Intervention Type OTHER

muscle area calculated on the T7 and T12 thoracic slices

28-day death

Deceased 28 days after intensive care admission

Data collection

Intervention Type OTHER

Demographic data:

Age, Sex, weight, height, main history and treatments.

\- Biological data: CRP, PCT, albumin, pre-albumin

analysis of thoracic scans

Intervention Type OTHER

muscle area calculated on the T7 and T12 thoracic slices

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Demographic data:

Age, Sex, weight, height, main history and treatments.

\- Biological data: CRP, PCT, albumin, pre-albumin

Intervention Type OTHER

analysis of thoracic scans

muscle area calculated on the T7 and T12 thoracic slices

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients hospitalized in intensive care for SARS-Cov-2 infection since january 2020
* Thoracic TDM within the 30 day preceding ICU admission and up to 24 hours after ICU admission

Exclusion Criteria

* Pregnancy
* Neuromuscular disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maxime NGUYEN

Role: CONTACT

380293528 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NGUYEN 2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.